Literature DB >> 6366827

Placental drug transfer: effects of gestational age and species.

G W Mihaly, D J Morgan.   

Abstract

The available evidence suggests that for most drugs, adverse effects in the fetus may vary with gestational state and among species due to: (i) changes in the fetal exposure to the drug (i.e. due to changes in the pharmacokinetics of the drug in the mother and/or the fetus), or to (ii) changes in the susceptibility of the fetus to the drug. The fetal exposure to a drug during gestation is influenced more by the varying capacity of mother and/or fetus to eliminate the drug than by any intrinsic 'barrier' phenomenon at the placenta. Although differential maternal/fetal protein binding, active transplacental transport processes and 'ion-trapping' effects may influence the fetal exposure of some drugs, the main mechanisms by which fetal exposure may be modulated during pregnancy are via the capacity for irreversible drug elimination--by the fetus or, less often, by the placenta. The susceptibility of a fetus to adverse drug reactions is determined by the ontogeny of vital processes and the nature of the interaction between the drug and the process. Hence 'gestational state' and 'species' dependent differences in adverse drug effects, in the presence of a constant level of exposure of drug, reflect the time dependent appearance of these processes and the differences in ontogeny of the processes among species. At present, no studies have attempted to relate the measured fetal drug exposure to the intensity of a drug response at different stages of gestation or among species. Although there is a dearth of information in this field, it is apparent that in all species the placentas of all species pose little obstruction to the passage of xenobiotics (including drugs), to the fetus. The consequence of this exposure will depend on a myriad of pharmacokinetic and pharmacodynamic considerations for a given substance in a given species. Hence the outcome cannot be predicted, but must be empirically determined. Extrapolation of findings among different drugs, species and gestational states must be undertaken with caution, recognizing the above considerations and limitations.

Mesh:

Substances:

Year:  1983        PMID: 6366827     DOI: 10.1016/0163-7258(83)90015-3

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  10 in total

1.  Placental transfer and tissue distribution of thiopental in the pregnant rat.

Authors:  A Celardo; F Passerini; M Bonati
Journal:  J Pharmacokinet Biopharm       Date:  1989-08

Review 2.  Targeted drug delivery for maternal and perinatal health: Challenges and opportunities.

Authors:  Anjali Sharma; Nirnath Sah; Sujatha Kannan; Rangaramanujam M Kannan
Journal:  Adv Drug Deliv Rev       Date:  2021-08-26       Impact factor: 17.873

3.  Differences in the binding of quinine and quinidine to plasma proteins.

Authors:  G W Mihaly; M S Ching; M B Klejn; J Paull; R A Smallwood
Journal:  Br J Clin Pharmacol       Date:  1987-12       Impact factor: 4.335

4.  Simultaneous quantification of methadone, cocaine, opiates, and metabolites in human placenta by liquid chromatography-mass spectrometry.

Authors:  Ana de Castro; Marta Concheiro; Diaa M Shakleya; Marilyn A Huestis
Journal:  J Anal Toxicol       Date:  2009-06       Impact factor: 3.367

5.  FcRn is not the receptor mediating the transfer of serum IgG to colostrum in pigs.

Authors:  Cuncun Ke; Yonghe Ma; Dengke Pan; Zihui Wan; Tao Feng; Dawei Yu; Xiaojuan Liu; Haitao Wang; Minjie Du; Linhua Huang; Yifu Zhang; Lijuan Du; Xifeng Wang; Kongpan Li; Di Yu; Ming Zhang; Jinwei Huang; Junwei Qu; Liming Ren; Yanzhong Hu; Gengsheng Cao; Xiaoxiang Hu; Sen Wu; Haitang Han; Yaofeng Zhao
Journal:  Immunology       Date:  2021-04-15       Impact factor: 7.215

Review 6.  Methods to identify and characterize developmental neurotoxicity for human health risk assessment. III: pharmacokinetic and pharmacodynamic considerations.

Authors:  D C Dorman; S L Allen; J Z Byczkowski; L Claudio; J E Fisher; J W Fisher; G J Harry; A A Li; S L Makris; S Padilla; L G Sultatos; B E Mileson
Journal:  Environ Health Perspect       Date:  2001-03       Impact factor: 9.031

Review 7.  A comparison of the histological structure of the placenta in experimental animals.

Authors:  Satoshi Furukawa; Yusuke Kuroda; Akihiko Sugiyama
Journal:  J Toxicol Pathol       Date:  2014-04-30       Impact factor: 1.628

Review 8.  A Review of Nanotechnology for Treating Dysfunctional Placenta.

Authors:  Huabo Jiang; Li Li; Dan Zhu; Xinyao Zhou; Yongsheng Yu; Qian Zhou; Luming Sun
Journal:  Front Bioeng Biotechnol       Date:  2022-03-24

9.  The effects of maternally administered methadone, buprenorphine and naltrexone on offspring: review of human and animal data.

Authors:  W O Farid; S A Dunlop; R J Tait; G K Hulse
Journal:  Curr Neuropharmacol       Date:  2008-06       Impact factor: 7.363

Review 10.  Incorporating children's toxicokinetics into a risk framework.

Authors:  Gary Ginsberg; William Slikker; James Bruckner; Babasaheb Sonawane
Journal:  Environ Health Perspect       Date:  2004-02       Impact factor: 9.031

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.